Cytopeutics Pte. Ltd.   Report issue

For profit Phase 2
Founded: Selangor Malaysia (2005)

Organization Overview

First Clinical Trial
2011
NCT01459640
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Cytopeutics Sdn Bhd | Cytopeutics Sdn. Bhd.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Graft vs Host Disease (Phase 2)

Infarction (Phase 2)

Infarction, Middle Cerebral Artery (Phase 2)

Ischemia (Phase 2)

Osteoarthritis (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 5
  • # of Trial APIs: 4